Group 1 - The core transaction involved 7.496 million shares of Bluestar Bio, with a total transaction value of 38.0047 million yuan, accounting for 39.16% of the total trading volume on that day [1][2] - The transaction price was 5.07 yuan per share, which represents a discount of 1.55% compared to the market closing price of 5.15 yuan [1][2]

Core Viewpoint - Jiangsu Lanfeng Bio-chemical Co., Ltd. has signed a settlement and debt waiver agreement with its controlling shareholder, Jiangsu Suhua Group Co., Ltd., to resolve investor litigation and debt issues, which is expected to alleviate the company's debt pressure and optimize its capital structure [1][7]. Summary by Sections Overview of the Settlement and Debt Waiver - The company faced investor lawsuits due to information disclosure violations, resulting in a compensation requirement of RMB 22,766,475.6, including overdue interest and litigation costs [2]. - As of July 31, 2025, the company owed Jiangsu Suhua Group a total of RMB 83,600,036.66, comprising RMB 59,200,719.70 in principal and RMB 24,399,316.96 in interest [2]. - The company has reached a settlement with Jiangsu Suhua Group regarding the investor lawsuits and debt waiver [2]. Key Terms of the Agreement - Jiangsu Suhua Group will bear a total compensation responsibility of RMB 17,157,200.73 for the investor lawsuits, which will be deducted from the company's outstanding loans to the group [5]. - The agreement includes a waiver of RMB 6,000,000 in interest debt by Jiangsu Suhua Group, which is unconditional and irrevocable [5]. - Following the agreement, the company will not pursue any further claims related to the investor lawsuits against Jiangsu Suhua Group or its management [6]. Impact of the Agreement on the Company - The total amount involved in the settlement and debt waiver is RMB 23,157,200, which will help reduce the company's debt burden and improve its asset-liability structure [7]. - The company will adjust its liabilities according to relevant accounting standards based on the audit results [7].

Group 1 - The board of directors of Jiangsu Lanfeng Biological Chemical Co., Ltd. held its 26th meeting on September 3, 2025, via communication methods, with all 8 directors present [1][2] - The board approved the signing of a settlement and debt waiver agreement with Jiangsu Suhua Group Co., Ltd., which is expected to alleviate the company's debt pressure and optimize its asset-liability structure [1] - The agreement does not constitute a related party transaction and does not harm the interests of minority shareholders [1]

Group 1 - The company announced that it will hold the 26th meeting of the 7th Board of Directors on September 3, 2025 [1] - The company approved the proposal regarding the signing of a settlement and debt waiver agreement [1] - The settlement and debt waiver agreement was reached with the former controlling shareholder, Jiangsu Suhua Group Co., Ltd., concerning investor litigation claims and debt waiver [1]

（文章来源：证券日报） 证券日报网讯 9月3日晚间，蓝丰生化发布公告称，公司第七届董事会第二十六次会议审议通过了《关 于公司签署和解及债务豁免协议的议案》。 ...

格隆汇9月3日丨蓝丰生化(002513.SZ)公布，公司于2025年9月3日召开第七届董事会第二十六次会议， 审议通过了《关于公司签署和解及债务豁免协议的议案》，就投资者诉讼索赔案件及债务豁免与时任控 股股东江苏苏化集团有限公司（简称"苏化集团"）达成和解并签署了《和解及债务豁免协议》。公司本 次与苏化集团签订《和解及债务豁免协议》，涉及的承担赔偿责任和债务豁免金额合计2,315.72万元， 协议的签署有利于减轻公司债务压力，优化公司资产负债结构，公司将依据《企业会计准则》相关规定 对已计提相应的负债进行调整，具体金额以审计结果为准。 ...

Core Viewpoint - The company has reached a settlement agreement with its controlling shareholder, Jiangsu Suhua Group Co., Ltd., regarding investor litigation claims and debt waiver, which will alleviate the company's debt pressure and optimize its capital structure [1] Summary by Relevant Sections - **Settlement Agreement**: The company signed a "Settlement and Debt Waiver Agreement" with Jiangsu Suhua Group, involving a total compensation and debt waiver amount of 23.1572 million yuan [1] - **Debt Pressure Relief**: The agreement is expected to reduce the company's debt burden and improve its asset-liability structure [1] - **Accounting Adjustments**: The company will adjust the relevant liabilities in accordance with the "Enterprise Accounting Standards," with specific amounts to be determined based on audit results [1]

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-043 江苏蓝丰生物化工股份有限公司 关于签署《和解及债务豁免协议》的公告 2、根据法院已生效判决及相关其他文书显示，上述投资者诉讼事项公司需 赔偿投资者损失本金人民币22,766,475.6元及逾期利息、诉讼费、执行费等。为 了维护公司及全体股东的合法权益，公司就前述事项已向时任董事长、总经理及 1 控股股东苏化集团发出《律师函》，要求其对投资者诉讼案件给公司造成的损失 承担相应赔偿责任。 3、截至2025年07月31日，公司尚欠苏化集团借款本息人民币83,600,036.66 元（其中本金59,200,719.70元，利息24,399,316.96元）。 近日，为了尽快落实和推进本次追偿事项，公司就上述投资者诉讼索赔案件 及相应债务豁免事项与时任控股股东苏化集团达成和解并签署了《和解及债务豁 免协议》。 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 江苏蓝丰生物化工股份有限公司（以下简称"公司"或"蓝丰生化"）于 2025年9月3日召开第七届董事会第二十六次会议，审议通过了《关于公司签署和 解 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-044 表决结果：8 票同意，0 票反对，0 票弃权。 具体详见 2025 年 9 月 4 日刊登在公司指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）及《上海证券报》、《证券时报》、《中国证券报》上 的相关公告。 三、备查文件 江苏蓝丰生物化工股份有限公司 第七届董事会第二十六次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"）第七届董事会第二十 六次会议于 2025 年 9 月 3 日以通讯方式召开。本次会议已于 2025 年 9 月 2 日以 微信、电子邮件的方式通知全体董事，经第七届董事会全体董事同意豁免会议通 知时间要求。本次会议由公司董事长郑旭先生主持，应出席董事 8 人，实际出席 董事 8 人，公司高级管理人员列席会议。本次会议的召集、召开及表决程序符合 《公司法》和《公司章程》的规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于公司签署和解及债务豁免协议的议案》 经审核， ...

Group 1 - The company has announced the lifting of restrictions on 1,339,746 shares, accounting for 0.357% of the total share capital [1] - Following the completion of a non-public share issuance, the company's total share capital increased from 340,086,278 shares to 373,936,278 shares, and subsequently to 375,280,278 shares after various stock incentive plans and repurchases [2] - The shareholders applying for the lifting of restrictions, Ren Wenbin and Chen Jing, have committed to not transferring their shares for specified periods based on the performance compensation agreements [3][4] Group 2 - The performance compensation agreement stipulates that if the audited net profits of Ark Pharmaceutical for 2015, 2016, and 2017 fall below certain thresholds, the shareholders must compensate the company [5] - The company has initiated legal proceedings against the shareholders for failing to fulfill their performance compensation obligations, resulting in a court ruling requiring them to pay a total of 403.1 million yuan in compensation [6] - The lifting of share restrictions does not involve any non-operating fund occupation or violations of guarantees that could harm the company's interests [6] Group 3 - The financial advisor has confirmed that the shareholders have strictly adhered to their commitments regarding the lifting of share restrictions, and the process complies with relevant laws and regulations [7]